The Stimulant Named After a Nobel Laureate's Hospital
For 27 years, you could walk into a French pharmacy and buy ibogaine over the counter. Not as an addiction treatment, that application was still decades away, but as an "anti-fatigue" stimulant called Lambarène. It launched in 1939, sold in 8 mg tablets (0.20 g of iboga extract per tablet, according to the French drug-policy publication ASUD), and stayed on shelves until 1966. Endurance athletes used it. A volcanologist wrote about taking it before descending into a cave system. And the name itself points to one of the more unusual footnotes in ibogaine's history: Albert Schweitzer.
The Plant and the Company Behind the Tablet
Lambarène came from the same plant every modern ibogaine treatment center still sources from today: Tabernanthe iboga, the root bark shrub native to Gabon. The 1930s extract was labeled under an old regional species name that botanists have since folded back into iboga itself, so some older sources describe it as a technically distinct plant. It wasn't. Same root, same alkaloid, 90 years apart.
The tablets came out of the Houdé laboratory, a French pharmaceutical manufacturer. Houdé put the extract into 8 mg tablets in 1939 and marketed it as a neuromuscular stimulant for fatigue, depression, and recovery from infectious disease. The groundwork traces to a 1939 doctoral thesis in Paris studying an iboga-derived extract from Gabon, and Houdé turned that research into a commercial product the same year, a fast turnaround from thesis to pharmacy shelf even by the standards of 1930s drug regulation.
Who Albert Schweitzer Actually Was
Schweitzer earned his M.D. in 1912 and in early 1913 opened a hospital at Lambaréné, a town on the Ogooué River in what was then French Equatorial Africa and is today Gabon. He ran that hospital, treating patients across equatorial Africa with minimal resources, until his death in 1965. In 1952 he won the Nobel Peace Prize and used the prize money to fund a leper colony at the same site. By the time Lambarène the drug hit French pharmacies, Schweitzer was already internationally known as, in the words of one retrospective on his legacy, proof "that there were still 'good people'" in the aftermath of two world wars.
That's the connection worth being precise about. According to ASUD, the tablet's formulation was "reportedly inspired by Dr. Schweitzer, a great walker and tireless explorer," meaning the product borrowed his reputation and the name of his hospital town, not necessarily his direct medical input. Schweitzer didn't formulate Lambarène or run clinical trials on it. The manufacturer named a stimulant pill after the most famous doctor associated with Gabon, the place ibogaine comes from, and let the association do the marketing. It's a trademark story more than a medical collaboration, and most retellings blur that line.
From Pharmacy Shelf to Doping Scandal
Lambarène wasn't marketed as a party drug or even explicitly as a psychedelic. It was sold as a "neuromuscular stimulant" indicated for depression, convalescence, infectious disease recovery, and, in ASUD's phrasing, "abnormal physical and intellectual effort." At the microdose range the tablets delivered, somewhere in the same territory researchers still study today for fatigue and cognitive load, the hallucinogenic potential of ibogaine is negligible. What it does instead is blunt the subjective experience of exhaustion, which is exactly what post-war endurance athletes wanted.
French volcanologist Haroun Tazieff described his own experience with Lambarène in his book Le Gouffre de la Pierre Saint-Martin, about a 1952 cave expedition, one of the few firsthand written accounts of the drug from a non-medical user. By the 1950s and 60s it had become, as ASUD puts it, "one of the preferred doping agents of post-war athletes." That popularity is precisely what ended it. France pulled Lambarène from the market in 1966 and banned ibogaine sales outright. Decades later, the International Olympic Committee formally classified ibogaine as a doping substance in 1989, officially closing a loop that had already been closed in practice for over 20 years.
There's a genuine irony buried in that timeline that's easy to miss: ibogaine wasn't banned because regulators thought it was dangerous to users. It was banned, first in France and later by the IOC, because it worked too well as a performance enhancer. The addiction-interrupting and brain-repair research that drives interest in ibogaine today came afterward, and almost by accident.
The Accident That Redirected Ibogaine's History
In 1962, a 19-year-old heroin user named Howard Lotsof tried ibogaine recreationally, at a chemist friend's suggestion, expecting a psychedelic experience similar to what Timothy Leary and others in his circle were exploring at the time. What he got instead was something nobody was looking for: his heroin withdrawal symptoms stopped, and his craving for the drug didn't return for months. Lotsof spent the next four decades pushing that observation into formal research, eventually becoming the figure most credited with turning ibogaine from a forgotten French stimulant into a subject of serious addiction-medicine study.
ASUD's history also notes a darker, harder-to-verify thread from the same era: a CIA-run study in the 1950s on a population of African-American patients with morphine addiction, whose results remain classified. We haven't been able to independently confirm the details of that program, and we're flagging it here as a claim from a secondary source rather than an established fact, but it's a reminder that ibogaine's path from Gabonese root bark to French pharmacy to American addiction research passed through some genuinely murky chapters before it reached the clinical research being done now.
What This History Actually Tells Us
Two things stand out that aren't the obvious takeaway. First, ibogaine's first commercial life had nothing to do with addiction. It was a mainstream, legally sold energy drug for four decades before anyone connected it to opioid withdrawal, which means the compound's full pharmacological range, stimulant at low doses, anti-addictive and possibly neuroregenerative at treatment doses, has been documented for nearly a century, not discovered recently. Second, the plant ibogaine comes from was first isolated from Gabonese root bark in 1901, chemically synthesized in full by 1966, and sold as a stimulant for most of the time in between. The modern clinical conversation is really a return to a compound Europe already knew intimately, not a new discovery.
None of this changes the real risk profile that governs how ibogaine should be used today. QT interval prolongation is a documented cardiac risk regardless of how the compound was marketed in 1939, and the safety protocols that matter now, cardiac screening, physician supervision, lab-verified dosing, exist precisely because unsupervised use, even at the modest doses French pharmacies once sold over the counter, carries real risk. The history is a genuinely good story. It isn't a safety argument.
Sources
ASUD (Auto-Support des Usagers de Drogues), "Une brève histoire de l'iboga"; Kew Plants of the World Online; Wikipedia, "Albert Schweitzer" and "Howard Lotsof"; Nobel Prize biographical archive.